EUVIMEDOpdag EUVIMED
Kontrollierte klinische StudieMultizentrische StudieOpen access · CC BY 4.0

The Impact of Underlying Plaque Characteristics Following the Third‐Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12‐Months

Alp Aytekin iD, Masaru Seguchi iD, Erion Xhepa, Michael Haude, Adrian Wlodarczak, René J van der Schaaf, Jan Torzewski, Hector M Garcia-Garcia, Ron Waksman iD, Michael Joner

Catheterization and Cardiovascular Interventions · 2025

DOI: 10.1002/ccd.31486 ↗

At a glance

Kontrollierte klinische Studie in Catheterization and Cardiovascular Interventions, 2025. Written by Alp Aytekin and 9 co-authors. Institution: Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany. Major MEDLINE topics: Absorbable Implants, Coronary Artery Disease, Magnesium, Percutaneous Coronary Intervention. Cited 1 times so far (Crossref); 19 references. The full text is freely available (open access, CC BY 4.0). Funded by: The authors are grateful to the rest of the BIOMAG-I Trial investigators, especially Dr. Bert Ferdinande, Dr. Javier Escaned, Dr. Juan F Iglesias, Dr. Johan Be….

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Third‐generation resorbable magnesium scaffold (RMS) was developed with stronger mechanical properties and thinner struts compared to its predecessor. This study aimed to assess the influence of the OCT‐derived underlying plaque characteristics on in‐scaffold late lumen loss (LLL) in patients treated with RMS up to 12‐months.

Methods

Patients enrolled in the BIOMAG‐I trial and who underwent OCT imaging before and after the index procedure were included in the current analysis. The acquired intravascular imaging data were evaluated to assess the presence of fibrous, calcific, or lipidic lesions. We calculated the proportions of each plaque feature per pullback and assessed their correlation with LLL obtained at 6‐ and 12‐months follow‐up. In addition, we investigated the potential impact of scaffold edge dissection and strut malapposition on in‐scaffold LLL.

Results

Eighty‐four patients and 84 lesions were evaluated in the current analysis. There was no significant correlation between the underlying plaque characteristic and in‐scaffold LLL at 6‐months ( p = 0.79 for fibrous, p = 0.88 for calcific, p = 0.67 for lipid lesions). This trend was similar at 12 months follow‐up ( p = 0.56 for fibrous, p = 0.75 for calcific, p = 0.69 for lipid lesions). The presence or absence of edge dissection did not influence the degree of in‐scaffold ‐ ( p = 0.51 at 6‐months, p = 0.68 at 12‐months follow‐up) or in‐segment LLL ( p = 0.88 at 6‐months, p = 0.70 at 12‐months follow‐up).

Conclusion

The underlying plaque characteristics, edge dissection or strut malapposition had no significant impact on in‐scaffold LLL following DREAMS 3 G implantation up to 12 months. This suggests better device performance irrespective of the underlying plaque characteristics. Trial Registration ClinicalTrials.gov ID: NCT04157153.

Subjects

MeSH terms (MEDLINE)

Absorbable ImplantsCoronary Artery DiseaseMagnesiumPercutaneous Coronary InterventionPlaque, AtheroscleroticTomography, Optical CoherenceVascular CalcificationAgedFemaleHumansMaleMiddle AgedCoronary VesselsFibrosisPredictive Value of TestsProspective StudiesProsthesis DesignTime FactorsTreatment Outcome

Author keywords

bioresorbable magnesium scaffoldcoronary artery diseaseoptical coherence tomographypercutaneous coronary interventionplaque characteristics

Substances

Magnesium

Authors and institutions

  • Klinik für Herz- und Kreislauferkrankungen, Deutsches Herzzentrum München, Munich, Germany.
  • Medical Clinic I, Rheinland Klinikum Neuss GmbH, Lukaskrankenhaus, Neuss, Germany.
  • Department of Cardiology, Miedziowe Centrum Zdrowia SA, Lubin, Poland.
  • Faculty of Medicine, Wroclaw University of Science and Technology, Wroclaw, Poland.
  • Department of Interventional Cardiology, OLVG, Amsterdam, The Netherlands.
  • Cardiovascular Center Oberallgäu-Kempten, Kempten, Germany.

ORCID profiles: Alp Aytekin, Masaru Seguchi, Ron Waksman

Funding

  • The authors are grateful to the rest of the BIOMAG-I Trial investigators, especially Dr. Bert Ferdinande, Dr. Javier Escaned, Dr. Juan F Iglesias, Dr. Johan Be…

Cite

APA

Aytekin, A., Seguchi, M., Xhepa, E., Haude, M., Wlodarczak, A., van der Schaaf, R. J., Torzewski, J., Garcia-Garcia, H. M., Waksman, R., & Joner, M. (2025). The Impact of Underlying Plaque Characteristics Following the Third‐Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12‐Months. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31486

Vancouver

Aytekin A, Seguchi M, Xhepa E, Haude M, Wlodarczak A, van der Schaaf RJ, et al. The Impact of Underlying Plaque Characteristics Following the Third‐Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12‐Months. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31486

BibTeX
@article{Aytekin2025,
  author = {Aytekin, Alp and Seguchi, Masaru and Xhepa, Erion and Haude, Michael and Wlodarczak, Adrian and van der Schaaf, René J and Torzewski, Jan and Garcia-Garcia, Hector M and Waksman, Ron and Joner, Michael},
  title = {The Impact of Underlying Plaque Characteristics Following the Third‐Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12‐Months},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2025},
  doi = {10.1002/ccd.31486}
}
Start for free →